Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: A phase I-II study

Oncology Reports

Volumn 15, Issue 5, 2006, Pages 1201-1204

  Stathopoulos, George P ^a   Boulikas, Teni ^b,c   Vougiouka, Maria ^b,c   Rigatos, Sotirios K ^a   Stathopoulos, John G ^a  

^a Errikos Dunant Hospital   (Greece)

^b Regulon Inc   (United States)

^c Regulon SA   (Greece)

Author keywords

Gemcitabine; Liposomal cisplatin; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; LIPOPLATIN; LIPOSOME;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL DIFFERENTIATION; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIFFERENTIATION; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE;

EID: 33745002266     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.5.1201     Document Type: Article

References (17)

1. Rosenberg B: Platinum complexes for the treatment of cancer: why the search goes on. In: Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. Lippert B (ed). Zurich, Verlag Helvetica Chimica Acta, pp3-12, 1999.
2. Sorenson C and Eastman A: Mechanism of cis-diamminedichloroplatinum (II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 48: 4484-4488, 1988.
3. Einhorn LH, Williams SD, Loehrer PJ, Birch R, Drasga R and Omura G: Evaluation of optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors: a Southeastern Cancer Study group protocol. J Clin Oncol 7: 387-391, 1989. (Pubitemid 19075021)
4. Aabo K, Adams M, Adnitt P, Alberts DS, Athanazziou A, Barley V, Bell DR, Bianchi U, Bolis G, Brady MF, Brodovsky HS, Bruckner H, Buyse M, Canetta R, Chylak V, Cohen CJ, Colombo N, Conte PF, Crowther D, Edmonson JH, Gennatas C, Gilbey E, Gore M, Guthrie D and Yeap BY: Chemotherapy in advanced ovarian cancer: four systematic meta-analysis of individual patient data from 37 randomized trials. Br J Cancer 78: 1749-1487, 1998.
5. Kaufman D, Raghavan D, Carducci M, Carducci M, Levine EG, Murphy B, Aisner J, Kuzei T, Nicol S, Oh W and Stadier W: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18: 1921-1927, 2000. (Pubitemid 30261930)
6. Pignon JP, Bourhis J, Domenge C and Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355: 949-955, 2000. (Pubitemid 30148259)
7. Non-Small-Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer, a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311: 899-909, 1995.
8. Hayes D, Cvitkovic E, Golfey R, Golbey RB, Scheiner E, Helson L and Krakoff IH: High dose cis-platinum diaminedichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39: 1372-1378, 1977.
9. Gandara DR, Nahhas NA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, Homesley HD, Braly P, Ritch PS and Weisberg SR: Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol 13: 490-496, 1995.
10. Sculier JP, Lafitte JJ, Lecomte J, Berghmans T, Thiriaux J, Florin MC, Efremidis A, Alexopoulos CG, Recloux P, Ninane V, Mommen P, Paesmans M and Klastersky J: European Lung Cancer Working Party: a three-arm phase III randomized trial comparing combinations of platinum derivatives ifosfamide and/or gemcitabine in stage IV non-small cell lung cancer. Ann Oncol 13: 874-882, 2002. (Pubitemid 34752682)
11. Tognoni A, Pensa F, Vaira F, Vigani A, Caness P, Sinaccio G and Pronzato P: A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer. J Chemother 14: 296-300, 2002. (Pubitemid 34734575)
12. Burris HA III, Moore MJ, Anderson J, Green MR, Rothernberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and van Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
13. Heinemann V, Wilke H, Mergenthaler HG, Clemens M, Konig H, Illiger HJ, Arning M, Schalhorn A, Possinger K and Fink U: Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer. Ann Oncol 11: 1399-1403, 2000.
14. Stathopoulos GP, Rigatos SK, Dimopoulos MA, Giannakakis T, Foutzilas G, Kouroussis C, Janninis D, Aravantinos G, Androulakis N, Agelaki S, Stathopoulos JG and Georgoulias V: Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 14: 388-394, 2003. (Pubitemid 36367415)
15. Van Moorsel CJ, Smid K, Voorn DA, Bergman AM, Pinedo HM and Peters GJ: Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines. Int J Oncol 22: 201-207, 2003.
16. Stathopoulos GP, Boulikas T, Vougiouka M, Deliconstantinos G, Rigatos S, Darli E, Viliotou V and Stathopoulos JG: Pharmacokinetics and adverse reactions of a new liposomal cisplatin (lipoplatin): phase I study. Oncol Rep 13: 589-595, 2005.
17. Miller AB, Hoogstraten B, Staquet M and Winkler A: (WHO) Reporting results of cancer treatment. Cancer 47: 207-214, 1981. (Pubitemid 11167383)